SUMMARY

Regulatory scrutiny has focused on the direct and indirect drivers on MSLs' activities. Therefore, companies should realize that the symbol (what function the MSL program reports to, what advanced degrees MSLs hold) does not matter as much as the substance (what MSLs are actually expected to do, who applies the greatest pressures on MSL objectives) when it comes to evaluating activity drivers. It now looks like the golden age of regulating industry's conduct is upon Pharma. Order this article and learn more ...

Topics covered include:

• Training Functional Teams to Collaborate Compliantly with MSLs
• What is Your Company’s Performance Metrics for MSLs?
• Whose Rules? Whose Standards?
• Relevance and Congruence

More than ever, it is important to educate physicians about new drugs and to keep this education separate from the marketing function of the company yet aligned with commercial goals.

This Special Supplement to Pharma Markeing News is critical reading for pharmaceutical companies and physician education service providers wishing to understand the new roles of key opinion leader physicians (KOLs) and medical science liaisons (MSLs) in the physician education process.

TABLE OF CONTENTS